Spectral AI's Cash Triples to $15.4M, Posts Q4 Profit; Issues 2026 Revenue Guidance
Summary
Spectral AI announced strong financial improvements, with cash tripling to $15.4 million by year-end 2025, up from $5.2 million in 2024. The company also reported a net income of $0.6 million for Q4 2025, a significant turnaround from a $7.7 million loss in the prior year, and narrowed its full-year net loss to $7.6 million from $15.3 million. While Q4 and full-year 2025 revenues declined to $3.8 million and $19.7 million respectively, this was attributed to anticipated reductions in reimbursed R&D costs as the company nears completion of its BARDA contract's base phase and submitted its DeepView System's De Novo 510(k) application to the FDA. The company introduced 2026 revenue guidance of approximately $18.5 million, primarily from continued BARDA contract development. This comprehensive financial update, particularly the substantial cash increase and shift to Q4 profitability, provides critical new information for traders, building on the previously announced $31.7 million BARDA funding.
At the time of this announcement, MDAI was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.6M. The 52-week trading range was $1.04 to $3.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.